B
Bruno H. Ch. Stricker
Researcher at Erasmus University Rotterdam
Publications - 8
Citations - 1862
Bruno H. Ch. Stricker is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Population & Pharmacy. The author has an hindex of 7, co-authored 8 publications receiving 1790 citations.
Papers
More filters
Journal ArticleDOI
The Rotterdam Study: Objectives and design update
Albert Hofman,Guy Brusselle,Sarwa Darwish Murad,Cornelia M. van Duijn,Oscar H. Franco,André Goedegebure,M. Arfan Ikram,Caroline C W Klaver,Tamar Nijsten,Robin P. Peeters,Bruno H. Ch. Stricker,Henning Tiemeier,André G. Uitterlinden,Meike W. Vernooij +13 more
TL;DR: The rationale of the study and its design is given, and a summary of the major findings and an update of the objectives and methods are presented.
Journal ArticleDOI
Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
Matthijs L. Becker,Loes E. Visser,Ron H.N. van Schaik,Albert Hofman,André G. Uitterlinden,Bruno H. Ch. Stricker +5 more
TL;DR: In this article, the effect of the MATE1 rs2289669 polymorphism on the glucose lowering effect of metformin was analyzed in the Rotterdam Study, a population-based cohort study.
Journal ArticleDOI
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.
Laure Elens,Matthijs L. Becker,Vincent Haufroid,Albert Hofman,Loes E. Visser,André G. Uitterlinden,Bruno H. Ch. Stricker,Ron H.N. van Schaik +7 more
TL;DR: The CYP3A4*22 intron 6 SNP T-variant allele was associated with reduced CYP 3A4 activity, resulting in a better lipid lowering response to simvastatin, when data were adjusted for confounding factors.
Journal ArticleDOI
Potential Determinants of Drug-Drug Interaction Associated Dispensing in Community Pharmacies
Matthijs L. Becker,Matthijs L. Becker,Marjon Kallewaard,Peter W. J. Caspers,Tom Schalekamp,Bruno H. Ch. Stricker +5 more
TL;DR: The determinants identified in this review can be used to develop strategies to minimise patient harm resulting from DDIs and of the relation between DDI-associated dispensing and patient harm is recommended.
Journal ArticleDOI
Increasing Exposure to Drug-Drug Interactions Between 1992 and 2005 in People Aged ≥55 Years
TL;DR: A large number of people in the Netherlands aged ≥55 years are exposed to DDIs and this number has increased sharply between 1992 and 2005, and healthcare professionals should pay special attention to the potential risks of DDIs in these people, particularly if spironolactone is involved.